# Safety Study of Nivolumab to Treat Advanced or Metastatic Non-small Cell Lung Cancer

> **NCT03090737** · PHASE2 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 129 (actual)

## Conditions studied

- Non-Small Cell Lung Cancer

## Interventions

- **BIOLOGICAL:** Nivolumab

## Key facts

- **NCT ID:** NCT03090737
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-06-02
- **Primary completion:** 2021-02-16
- **Final completion:** 2022-03-14
- **Target enrollment:** 129 (ACTUAL)
- **Last updated:** 2022-12-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03090737

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03090737, "Safety Study of Nivolumab to Treat Advanced or Metastatic Non-small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT03090737. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*